Emily Wasserman
FiercePharma
Washington, DC, United States
Contact Emily
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Emily:
Biogen's MS drug Zinbryta tied to more serious side effects than Avonex: Advera
Biogen’s once-monthly MS drug Zinbryta nabbed FDA approval on Friday, but study data reflects more serious side effects than those for the company's older med, Avonex. The new treatment is safer than a competing treatment from Sanofi, however, according to a recent analysis. → Read More
Big Pharma steps up fight to defeat California drug pricing proposal
Big Pharma has already taken aim at a measure in California that would cap drug prices and take a big bite out of the state's $4.2B in drug spending. Now, the industry is stepping up its fight, funding a big share of the $68.4M opposition. → Read More
Sanders chastises U.S. reps over role in Gleevec CL battle
Earlier this week, top lawmakers in the House of lambasted U.S. trade officials for allegedly pressuring the Colombian government to reject a compulsory license for Novartis’ cancer med Gleevec. Senate peers are also weighing in on the issue and chastising the officials for bad behavior. → Read More
Tug-of-war over Novartis' Gleevec rights in Colombia escalates with U.S. lawmakers' challenge
Some lawmakers are up in arms after U.S. officials allegedly pressured the Colombian government to nix a compulsory license for Novartis’ cancer med, Gleevec. Now, they’re demanding answers from U.S. trade representatives. → Read More
American vets head to Cuba for animal health conference
Thawed diplomatic tensions between the U.S. and Cuba has led to a lot of developments, including more collaboration between stateside and Cuban veterinarians. American and Cuban vets recently had a powwow in Cuba at a conference organized by University of Pennsylvania School of Veterinary Medicine alumna Louise Wechsler. → Read More
Novartis would sell its Roche stake without a premium, CEO says
Novartis has been reluctant to sell its big stake in neighboring Swiss pharma Roche unless it got a premium. Now, the company is changing its tune. → Read More
Pharma's tarnished rep is slowly improving: Study
Pharma’s image hasn’t exact been squeaky clean lately given drug pricing probes and public pushback. But the industry’s reputation is improving a little, and some companies such as Bayer are still winning high marks with consumers, according to a recent study. → Read More
Takeda loses again to Hikma in gout drug patent battle
Takeda suffered a defeat in its battle to keep a competitor to its version of an ancient gout drug off the market. A federal court backed Hikma's right to sell a med with the same active ingredient as Takeda’s Colcrys because it's approved for an off-patent indication. → Read More
Compatriot drugmaker shares Valeant's appetite for dramatic price hikes: Report
Valeant and fellow Canadian pharma Concordia Healthcare share a similar appetite for M&A. Another thing the two companies have in common? A zest for dramatic drug price increases on older meds. → Read More
J&J not ready to throw in the towel in body powder suits
Johnson & Johnson may have lost two multimillion-dollar verdicts over its body powder products, but don’t expect the company to throw in the towel just yet. It intends to keep defending, an outside lawyer who has defended J&J said. → Read More
Clock is ticking on CL deal for Novartis' Gleevec, Colombia says
Novartis has agreed to work with Colombia to lower the price of its leukemia drug Gleevec to prevent the country from issuing a compulsory license for the med. But the clock is ticking on a deal, Colombian health officials said. → Read More
Drug price increases lower so far in 2016: Analysts
Drug price increases are lower so far in 2016 than in 2015, according to a note from Deutsche Bank analysts. The trend comes as some pharma companies such as Valeant face pushback for hiking prices for certain branded meds. → Read More
Animal health activists to KFC: Time to jump on the antibiotic-free train
Animal health activists have been pushing fast food chains to switch to antibiotic-free meat supplies. Now, one group has a message for Kentucky Fried Chicken: Time to jump on the bandwagon. → Read More
Vermont backs bill for increased drug pricing transparency
Some states are pushing for transparency on drug pricing, but Vermont is the first to make serious headway. The state's legislature recently passed a bill that would require drug companies to explain price increases on certain meds. → Read More
Stada agrees to play nice with activist investor for board overhaul
Germany’s Stada is accommodating requests from an activist investor to rejig its board of directors, agreeing to play nice instead of staging a pricey defense. → Read More
ViiV gets chatty to spur HIV patients toward drug therapy
ViiV Healthcare wanted to nudge patients to start HIV drug treatment soon after diagnosis. So the company recruited experienced patients for “Couch Talk," an educational program that offers some facts--and reassurance--about antiretroviral therapy. → Read More
Baxter leads in $1B-plus race for India injectables maker: ET
Baxter wants to expand in injectables and it figures that a $1 billion-plus deal for India’s Gland Pharma could be just the ticket. The healthcare giant has emerged as a front-runner for the buyout, sources told The Economic Times. → Read More
FDA warns of potentially fatal skin reactions to Lilly's Zyprexa
The FDA is warning about potentially fatal skin reactions tied to Eli Lilly’s antipsychotic Zyprexa (olanzapine) products. The news deals some unfavorable cards to Lilly as it competes in a crowded long-acting injectables market. → Read More
Phibro reports disappointing Q3 as regulatory woes take their toll
Phibro Animal Health has suffered after the FDA said that it would crack down on the company’s antibiotic for pigs. Phibro’s regulatory woes took their toll on Q3 earnings, with sales that rang in lower than last year’s numbers. → Read More
Want a celeb endorser? 'Minus one, multiply by 20,' expert says
Signing celebrities to market a drug can be like playing with fire, as some companies know well. But there are things drugmakers can do to minimize risk and get the most from their celeb endorsers, marketing experts say. → Read More